ARTICLE | Clinical News
LJPC-6417 regulatory update
April 29, 2013 7:00 AM UTC
La Jolla said FDA granted Orphan Drug designation for its LJPC-6417 to treat fibrodysplasia ossificans progressiva, a rare inherited disorder where muscle and connective tissue are replaced by bone. T...